Sign inJoin waitlistJoin the waitlist

Nikolai Podoltsev

Director, Hematology/Leukemia Tumor Board · Yale Cancer Center

Credentials: · · · ·

History

Malignant Hematology · Yale School of Medicine
Present
Yale School of Medicine
Present

Yale-New Haven Hospital
Chief Resident2026–Present
2023–2026
Yale University School of Medicine
2008–2010
Yale New Haven Hospital - Saint Raphael Campus
Chief ResidentUntil 2001
1997–2000
St. Petersburg State Pavlov Medical University
1995–1997
Pavlov First State Medical University of St. Petersburg
1997
St. Petersburg State Pavlov Medical University
1993–1995
First Pavlov State Medical University of St. Petersburg
1989–1993

Research

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
New England Journal of Medicine · 2019 · 1,078 citations
Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation
Case report · Nature Genetics · 2014 · 400 citations
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial
Blood · 2022 · 127 citations

Amer Zeidan
85 papers · 2 as a fellow
RS
Rory Shallis
51 papers
SG
Steven Gore
41 papers
Jan Bewersdorf
40 papers · 32 as a resident
Scott Huntington
36 papers · 1 as a fellow
Maximilian Stahl
34 papers
JS
Jessica Stempel
18 papers · 16 as a fellow
Lourdes Mendez
18 papers
Smith Giri
16 papers · 12 as a fellow
Natalia Neparidze
14 papers
Mark Litzow
13 papers
Martha Wadleigh
13 papers

Clinical trials

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Site PI · Recruiting · Phase 3
Novartis Pharmaceuticals
2026–2030
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Site PI · Recruiting · Phase 1, Phase 2
Aptose Biosciences Inc.
2019–2027